BRCA2 and ovarian cancer: The conclusions of this study suggested that BRCA1 mutation in TH patients may drive the clinical TH phenotype (based on elevated ovarian cancer risk and earlier age of breast cancer diagnosis vs subjects carrying a single pathogenic variant in BRCA2) [27].